SCLC brain metastasis treatments show improved survival and cognition in phase III trial

New research presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting suggests significant advancements in treating small cell lung cancer (SCLC) with brain metastases.

A randomized phase III study involving 304 patients found that brain MRI surveillance alone resulted in a 40 percent improvement in cognitive failure-free survival (CFFS) compared to the combination of brain MRI and prophylactic cranial irradiation (PCI). Patients receiving only MRI surveillance also showed improvements in quality-of-life outcomes and patient-reported measures during the first two years of the study.

In a separate finding from the same trial, patients with SCLC that had spread to the brain lived a median of 17 months following focused stereotactic radiosurgery (SRS), compared to nine months with advanced whole brain radiation therapy (WBRT). While SRS did not significantly improve the primary endpoint of time to neurocognitive decline, it showed no significant difference in neurologic death or serious treatment-related side effects. Researchers noted these findings allow for more individualized discussions regarding whether focused radiosurgery or whole brain treatment is appropriate for patients.